Literature DB >> 11801676

Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice.

Erika Cretney1, Kazuyoshi Takeda, Hideo Yagita, Moira Glaccum, Jacques J Peschon, Mark J Smyth.   

Abstract

We have previously implicated TNF-related apoptosis-inducing ligand (TRAIL) in innate immune surveillance against tumor development. In this study, we describe the use of TRAIL gene-targeted mice to demonstrate the key role of TRAIL in suppressing tumor initiation and metastasis. Liver and spleen mononuclear cells from TRAIL gene-targeted mice were devoid of TRAIL expression and TRAIL-mediated cytotoxicity. TRAIL gene-targeted mice were more susceptible to experimental and spontaneous tumor metastasis, and the immunotherapeutic value of alpha-galactosylceramide was diminished in TRAIL gene-targeted mice. TRAIL gene-targeted mice were also more sensitive to the chemical carcinogen methylcholanthrene. These results substantiated TRAIL as an important natural effector molecule used in the host defense against transformed cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11801676     DOI: 10.4049/jimmunol.168.3.1356

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  180 in total

Review 1.  Hepatocyte death: a clear and present danger.

Authors:  Harmeet Malhi; Maria Eugenia Guicciardi; Gregory J Gores
Journal:  Physiol Rev       Date:  2010-07       Impact factor: 37.312

Review 2.  Combining naturally occurring polyphenols with TNF-related apoptosis-inducing ligand: a promising approach to kill resistant cancer cells?

Authors:  Guillaume Jacquemin; Sarah Shirley; Olivier Micheau
Journal:  Cell Mol Life Sci       Date:  2010-05-29       Impact factor: 9.261

3.  TRAIL/DR5 plays a critical role in NK cell-mediated negative regulation of dendritic cell cross-priming of T cells.

Authors:  Mitsuhiro Iyori; Tong Zhang; Haddon Pantel; Bethany A Gagne; Charles L Sentman
Journal:  J Immunol       Date:  2011-08-10       Impact factor: 5.422

4.  In vivo eradication of MLL/ENL leukemia cells by NK cells in the absence of adaptive immunity.

Authors:  J Nakata; K Nakano; A Okumura; Y Mizutani; H Kinoshita; M Iwai; K Hasegawa; S Morimoto; F Fujiki; N Tatsumi; H Nakajima; Y Nakae; S Nishida; A Tsuboi; Y Oji; Y Oka; H Sugiyama; A Kumanogoh; N Hosen
Journal:  Leukemia       Date:  2013-11-13       Impact factor: 11.528

Review 5.  Are we really on the right TRAIL?

Authors:  Erika Cretney; Adam P Uldrich; Stuart P Berzins; Andreas Strasser; Dale I Godfrey; Mark J Smyth
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

Review 6.  Death receptors and caspases: role in lymphocyte proliferation, cell death, and autoimmunity.

Authors:  Sabine Adam-Klages; Dieter Adam; Ottmar Janssen; Dieter Kabelitz
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

7.  C-type lectin-like molecule-1 (CLL1)-targeted TRAIL augments the tumoricidal activity of granulocytes and potentiates therapeutic antibody-dependent cell-mediated cytotoxicity.

Authors:  Valerie R Wiersma; Marco de Bruyn; Ce Shi; Marloes J M Gooden; Maartje C A Wouters; Douwe F Samplonius; Djoke Hendriks; Hans W Nijman; Yunwei Wei; Jin Zhou; Wijnand Helfrich; Edwin Bremer
Journal:  MAbs       Date:  2015       Impact factor: 5.857

Review 8.  Immune surveillance of tumors.

Authors:  Jeremy B Swann; Mark J Smyth
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

Review 9.  Interferon-gamma and cancer immunoediting.

Authors:  Gavin P Dunn; Hiroaki Ikeda; Allen T Bruce; Catherine Koebel; Ravi Uppaluri; Jack Bui; Ruby Chan; Mark Diamond; J Michael White; Kathleen C F Sheehan; Robert D Schreiber
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

10.  Host immunity contributes to the anti-melanoma activity of BRAF inhibitors.

Authors:  Deborah A Knight; Shin Foong Ngiow; Ming Li; Tiffany Parmenter; Stephen Mok; Ashley Cass; Nicole M Haynes; Kathryn Kinross; Hideo Yagita; Richard C Koya; Thomas G Graeber; Antoni Ribas; Grant A McArthur; Mark J Smyth
Journal:  J Clin Invest       Date:  2013-02-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.